Colon cancer prevention by NSAIDS: What is the mechanism of action?

European Journal of Surgery, Supplement

Volumn 164, Issue 582, 1998, Pages 111-114

  Ahnen, Dennis J ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Colon cancer; Eyelooxygenase; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; SULINDAC; ANTINEOPLASTIC AGENT;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PREVENTION; CLINICAL TRIAL; COLON ADENOMA; COLON CANCER; DRUG MECHANISM; HUMAN; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; COLON POLYPOSIS; COLON TUMOR; PATHOLOGY; REVIEW;

ADENOMATOUS POLYPOSIS COLI; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; APOPTOSIS; COLONIC NEOPLASMS; HUMANS;

EID: 0032216792     PISSN: 1102416X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. 1. Alberts DS, Hixson L, Ahnen D, et al. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase. J Cell Biochem 1995; 22: 18-23.
2. 2. Beazer-Barclay Y, Levy DB, Moser AR, et al. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 1996; 17: 1757-1760.
3. 3. Cole P, Sateren W. The evolving picture of cancer in America. J Natl Cancer Inst 1994; 87: 159-160.
4. 4. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-1188.
5. 5. Gann PH, Manson JE, Glynn RJ, Hennekens CH. Low-dose aspirin and incidence of colorectal tumors in a randomized trial [see comments]. J Natl Cancer Inst 1993; 85: 1220-1224.
6. 6. Giardiello FM, Hamilton SR, Krush AJ. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-1316.
7. 7. Goldberg Y, Nassif II, Pittas A, et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996; 12: 893-901.
8. 8. Hale AJ, Smith CA, Sutherland LC, et al. Apoptosis: molecular regulation of cell death. Eur J Biochem 1996; 236: 1-26.
9. 9. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52: 237-245.
10. 10. Hixson LJ, Alberts DS, Krutzsch M, et al. Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers & Prevention 1994; 3: 433-438.
11. 11. Jacoby RF, Kantoci D, Murray ED, Wechter WJ. The effect of r-flurbiprofen on inhibition of polyp formation in the min mouse model. Gastroenterology 1996; 110: A555.
12. 12. Labayle D, Fischer D, Vielh P, Drouhin F, Pariente . A Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-639.
13. 13. Lancaster T, Silagy C. Aspirin and neoplasia of the digestive tract: is there a chemopreventive effect? Dig Dis 1994; 12: 170-176.
14. 14. Marnett LJ. Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Preventive Medicine 1995; 24: 103-106.
15. 15. Nugent KP, Farmer KC, Spigelman AD, Williams CB, Phillips RK. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993; 80: 1618-1619.
16. 16. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in APC knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-809.
17. 17. Parker AL, Kadakia SC, Maccini DM, et al. Disappearance of duodenal polyps in Gardner's syndrome with sulindac therapy. Am J Gastroenterol 1993; 88: 93-94.
18. 18. Parker SL, Tong T, Bolden S, Wingo PA Cancer statistics, 1996. CA 1996; 46: 5-27.
19. 19. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109: 994-998.
20. 20. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997; 57: 2909-2916.
21. 21. Piazza GA, Fryer BJ, van Stolk RU, et al. Selective apoptosis of neoplastic cells accompanies polyp regression in familial adenomatous polyposis (FAP) patients treated with FGN-1 (sulindac sulfone): evidence for a cyclooxygenase independent mechanism. Gastroenterology 1998.
22. 22. Piazza GA, Kulchak Rabm AL, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995; 55: 3110-3116.
23. 23. Piazza GA, Rahm AK, Finn T, et al. Apoptosis fully accounts for the growth inhibitory properties of sulindac metabolites by a mechanism independent of cyclooxygenase inhibition, cell cycle arrest or p53 mediation. Cancer Res 1997; 57: 2452-2459.
24. 24. Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987; 47: 5340-5346.
25. 25. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxy-genase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 4566-4571.
26. 26. Shiff SJ, Koutsos MI, Qiao L, Rigas B, Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996; 222: 179-188.
27. 27. Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995; 96: 491-503.
28. 28. Spagnesi MT, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994; 106: 362-366.
29. 29. Thompson HJ, Briggs S, Paranka NS, et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. J Natl Cancer Inst 1995; 87: 1259-1260.
30. 30. Thompson HJ, Jiang C, Lu J, et al. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res 1997; 57: 267-271.
31. 31. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
32. 32. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989; 157: 175-179.
33. 33. Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83-87.
34. 34. Wargovich MJ, Chen CD, Harris C, Yang E, Velasco M. Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int J Cancer 1995; 60: 515-519.